000			02854na a2200265 4500
003			H12O
005			20180417112622.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aBallestín Carcavilla, Claudio _91944 _eAnatomía Patológica
100			_aCastellano, Daniel _9882 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
245	0	0	_aBiological markers of cisplatin resistance in advanced testicular germ cell tumours _h[artículo]
260			_bClinical and Translational Oncology, _c2012
300			_a14(6):452-457.
500			_aFormato Vancouver: García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, et al. Biological markers of cisplatin resistance in advanced testicular germ cell tumours. Clin Transl Oncol. 2012;14(6):452-7.
501			_aPMID: 22634534
504			_aContiene 28 referencias
520			_aGerm cell tumours (GCTs) of the testis show exquisite sensitivity to treatment with cisplatin. Despite the high cure rates provided by platinum-based chemotherapy, 10-20% of patients die from progressive disease. Although various cellular pathways may influence cisplatin efficacy, their actual impact has not been comprehensively investigated in advanced GCTs. The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53 tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatin-based chemotherapy. MATERIALS AND METHODS: Paraffin-embedded tumour tissues from 84 patients with advanced GCT treated with cisplatin-based chemotherapy were analysed. Immunohistochemical expression of proteins p53 and mdm2, and the G1-phase cyclins D1 and D2 (CD1 and CD2) was assessed and correlated with the clinical course. RESULTS: The percentages of positive expression of p53, mdm2, CD1 and CD2 were 56, 57, 37.5 and 55%, respectively. From univariate analysis, there was no significant association between p53, mdm2 or CD1 expression and outcome. Instead, positive CD2 expression was found to be marginally associated with shorter median duration of progression-free survival (PFS) (p=0.06). In multivariate analysis, none of the molecular markers retained statistical significance with treatment response or survival. CONCLUSIONS: Tissular expression of p53, mdm2 and CD1 is not associated with prognosis or treatment response in patients with advanced GCT. Aberrant CD2 expression appears to further determine a shorter PFS. Larger and further studies are required to validate CD2 as a marker of cisplatin resistance.
710			_9330 _aServicio de Anatomía Patológica
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7030.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c7030 _d7030